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The elimination of measles in Iran
Measles is a febrile disease that is considered to be one 
of the world’s most contagious viral diseases. Despite 
the existence of a safe, available, inexpensive, and highly 
effective vaccine, measles is still a global imperative, 
causing more than 100 000 deaths per year, which could 
be prevented through vaccination.1
In 2019, when the Eastern Mediterranean region 
was experiencing its greatest upsurge in measles cases, 
Iran received a certificate for measles elimination in 
October 2019. Iran, with a population of approximately 
82 million, is the third country in the Eastern 
Mediterranean region that has achieved the status of 
measles elimination, after Oman and Bahrain, both 
of which have a relatively small population. However, 
without sustained attention, this certification can be 
taken away. The challenge for Iran is to maintain the 
interruption of measles transmission by sustaining a 
high population immunity. In 2018 and 2019, several 
countries in the European and Americas region lost 
their measles elimination status and therefore, great 
attention should be paid to this matter. Notably, Iran 
also received the certification for rubella elimination in 
May, 2019. The number of rubella cases had dramatically 
decreased from 1154 cases in 2000, to 33 cases in 2018. 
Here we summarise the successful components of Iran’s 
measles elimination strategy.
In 2003, Iran began implementing one of the largest 
mass immunisation campaigns against measles and 
rubella. Similar mass catch-up measles immunisation 
campaigns have been done in countries around the 
world, but in smaller populations or with a lower 
vaccination coverage.2–7 Much like the Pan American 
Health Organization’s measles elimination vaccination 
strategy, Iran’s national campaign consisted of three 
phases.8
The first phase, also known as the catch-up phase, 
began on Dec 6, 2003, and was targeted at those 
aged from 5 years to 25 years. At that time, the 
measles vaccine was administered in two doses, one at 
9 months and the other at 15 months of age, as per the 
routine national immunisation programme. Due to this 
campaign, within a month, the vaccination coverage 
reached more than 100% in the target group and a total 
of 33 579 082 people were immunised. Several factors 
contributed to the success of this nationwide mass 
vaccination campaign. The programme was advocated 
by the country’s supreme leader and president and 
coordinated with the assistance of the Ministry of 
Health and subordinate organisations of the UN, such 
as UNICEF and WHO. Intersectional collaborations 
were developed between governmental authorities, 
including the Armed Forces, Red Crescent, Ministry 
of Education, Islamic Republic of Iran Broadcasting, 
Ministry of Science, Research and Technology, Serum 
Institute of India (vaccine producer), and many others. 
An important step in the programme was vaccine 
procurement and management. 40 million doses of 
vaccine were supplied at high-quality levels and stored 
in cold chain equipment for transportation to urban 
and hard-to-reach rural areas. Due to safety reasons, 
auto-disable syringes were used for the injection of 
measles-rubella vaccines. Micro plans were separately 
designed for each province. The campaign was 
managed by high-ranking experts of the Ministry of 
Health at the national level and expert observers at the 
district and university level. National and international 
health experts conducted, supervised, and technically 
assessed the process of the immunisation and its 
outcome, such as the serum level of measles and 
rubella antibodies in vaccine recipients. All the adverse 
events following immunisation were recorded from 
the time of vaccination until 1 month after vaccination. 
Fortunately, the prevalence of adverse events was very 
low. After the first phase, the number of measles cases 
reduced from approximately 11 000 cases in 2003, to 
less than 100 cases in 2004, which continued to persist 
in subsequent years.9
The second phase, also known as the keep-up phase, 
began immediately after the first phase and aimed 
to maintain the measles and rubella immunisation 
coverage at more than 95%, which has been 
successfully sustained since 2003. Every year, a few 
cases of people with measles are reported in rural and 
urban areas as localised outbreaks, with an average 
number of 10–20 measles cases in each outbreak. 
Immediately after the introduction of an outbreak, a 
keep-up vaccination was done; the largest of these was 
carried out extensively in the southeast of Iran in 2015, 
due to increases in measles prevalence and non-Iranian 
travellers.
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By the third phase, also known as the follow-
up phase, the number of measles cases reduced 
substantially. Measles elimination is defined as the 
absence of endemic measles virus transmission in a 
defined geographical area for 12 or more consecutive 
months in the presence of a high-quality surveillance 
system. If a country maintains the interruption of 
endemic measles  virus transmission for a period of 
at least 36 months from the last known endemic 
case, it will meet the verification criteria for measles 
elimination. Thus, in 2018, we requested an 
elimination certificate after the presentation of our 
documents to WHO, and we were certified in October 
2019, in Tunisia.
The global coverage of the first dose of measles vaccine 
has plateaued at 85%, and the coverage of the second 
dose has risen steadily to 67%; however, these rates still 
remain insufficient to prevent outbreaks.10 Elimination 
of measles is a global health priority because as long 
as the virus continues to circulate in any region of the 
world, travel-related infections will be unavoidable, 
unless supplemental immunisation programs are 
implemented in highly vulnerable populations.
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